Ana Clemente-Sanchez
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ana Clemente-Sanchez has a total of 97 co-authors. Here are the top co-authors by number of shared publications:
Diego Rincón
Liver Unit, Department of Digestive Diseases Hospital General Universitario Gregorio Marañón Madrid, Spain; CIBERehd Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas Madrid, Spain
2 shared publications- Rafael Bañares
Department of Digestive Diseases, Instituto de Investigación Sanitaria, Hospital General Universitario Gregorio Marañón, Universidad Complutense Madrid, 28007 Madrid, Spain
2 shared publications - Ramon Bataller
Liver Unit, Hospital Clínic de Barcelona, Barcelona, Spain
2 shared publications Adelina Horhat
Regional Institute of Gastroenterology and Hepatology, Cluj-Napoca, Romania
1 shared publicationAdrián Narvaez
Liver Unit, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina
1 shared publicationAinhoa Fernández‐Yunquera
Liver Unit and Digestive Department Hospital General Universitario Gregorio Marañón Madrid Spain
1 shared publication
Latest Publications
- 5 April 2023
- Published by Elsevier in Gastroenterología y Hepatología
- Vol. 47 (2) , 199-205
Hepatic hemodynamic study: More than just HVPG measurement
- 5 April 2023
- Published by Elsevier in Gastroenterología y Hepatología
- Vol. 47 (2) , 199-205
Hepatic hemodynamic study: More than just HVPG measurement
- Top Cited Papers
- 4 February 2022
- Published by Elsevier in Journal of Hepatology
- Vol. 77 (1) , 191-205
Cigarette smoking and liver diseases
- 4 February 2022
- Published by Elsevier in Journal of Hepatology
- Vol. 77 (1) , 191-205
Top Cited PapersCigarette smoking and liver diseases
- Top Cited Papers
- 1 November 2021
- Published by Elsevier in Journal of Hepatology
- Vol. 75 (5) , 1026-1033
Identification of optimal therapeutic window for steroid use in severe alcohol-associated hepatitis: A worldwide study
- 1 November 2021
- Published by Elsevier in Journal of Hepatology
- Vol. 75 (5) , 1026-1033
Top Cited PapersIdentification of optimal therapeutic window for steroid use in severe alcohol-associated hepatitis: A worldwide study
- 3 August 2021
- Published by Frontiers Media SA in Transplant International
- Vol. 34 (11) , 2214-2225
HCV eradication in recurrent hepatitis C after liver transplantation normalizes enhanced endothelial activation
Background The increased risk of cardiovascular disease (CVD) conferred by hepatitis C virus (HCV) is especially relevant after liver transplantation (LT), but its mechanism is still not well defined. This study aimed to evaluate the influence of HCV eradication in inflammatory and endothelial activation markers after LT. Methods We evaluated inflammatory (TNF-alfa, IL-6, IL-8 and MCP-1) and endothelial activation (E-selectin, ICAM-1, VCAM-1 and MMP-9) markers before and after eradication in 45 LT recipients with HCV infection (LT+/HCV+) and 44 non-transplanted HCV-infected patients (LT-/HCV+). We also considered an additional group of 40 LT recipients without HCV infection (LT+/HCV-). Results LT+/HCV+ patients presented a higher endothelial activation status before eradication compared to LT+/HCV- patients. However, levels of E-selectin, ICAM-1, VCAM-1 and MMP-9 were comparable between LT+/HCV+ and LT-/HCV+ patients before eradication. HCV eradication decreased ICAM-1 (5466.55 pg/ml vs. 3354.88pg/ml, p<0.001) and VCAM-1 (10456.52 pg/ml vs. 6658.85 pg/ml, p<0.001) levels in LT+/HCV+ and LT-/HCV+ patients. Remarkably, HCV eradication restored levels of endothelial activation markers of LT+/HCV+ patients compared to that of LT+/HCV- patients. Conclusions HCV plays a major role in endothelial dysfunction after LT. Furthermore, HCV eradication restores endothelial activation despite the exposure to immunosuppressive therapy.
- 3 August 2021
- Published by Frontiers Media SA in Transplant International
- Vol. 34 (11) , 2214-2225
HCV eradication in recurrent hepatitis C after liver transplantation normalizes enhanced endothelial activation
Background The increased risk of cardiovascular disease (CVD) conferred by hepatitis C virus (HCV) is especially relevant after liver transplantation (LT), but its mechanism is still not well defined. This study aimed to evaluate the influence of HCV eradication in inflammatory and endothelial activation markers after LT. Methods We evaluated inflammatory (TNF-alfa, IL-6, IL-8 and MCP-1) and endothelial activation (E-selectin, ICAM-1, VCAM-1 and MMP-9) markers before and after eradication in 45 LT recipients with HCV infection (LT+/HCV+) and 44 non-transplanted HCV-infected patients (LT-/HCV+). We also considered an additional group of 40 LT recipients without HCV infection (LT+/HCV-). Results LT+/HCV+ patients presented a higher endothelial activation status before eradication compared to LT+/HCV- patients. However, levels of E-selectin, ICAM-1, VCAM-1 and MMP-9 were comparable between LT+/HCV+ and LT-/HCV+ patients before eradication. HCV eradication decreased ICAM-1 (5466.55 pg/ml vs. 3354.88pg/ml, p<0.001) and VCAM-1 (10456.52 pg/ml vs. 6658.85 pg/ml, p<0.001) levels in LT+/HCV+ and LT-/HCV+ patients. Remarkably, HCV eradication restored levels of endothelial activation markers of LT+/HCV+ patients compared to that of LT+/HCV- patients. Conclusions HCV plays a major role in endothelial dysfunction after LT. Furthermore, HCV eradication restores endothelial activation despite the exposure to immunosuppressive therapy.